administering to said animal an effective amount of a pipecolic acid derivative compound, wherein the nerve-related vision disorder is selected from the group consisting of visual impairments; orbital disorders; disorders of the lacrimal apparatus; disorders of the eyelids; disorders of the conjunctiva; disorders of the cornea; cataract; disorders of the uveal tract; disorders of the retina; disorders of the optic nerve or visual pathways; free radical induced eye disorders and diseases; immunologically-mediated eye disorders and diseases; eye injuries; and symptoms and complications of eye disease, eye disorder, and eye injury, and wherein said compound is selected from the group consisting of




wherein n is 1; 2; or 3;

4-(4-methoxyphenyl)butyl (2S)-1-[2-(3,4,5-trimethoxyphenyl)acetyl]hexahydro-2-pyridinecarboxylate;

4-(4-methoxyphenyl)butyl (2S)-1-[2-(3,4,5-trimethoxyphenyl)acryloyl]hexahydro-2-pyridinecarboxylate;

4-(4-methoxyphenyl)butyl (2S)-1-[2-(3,4,5-trimethoxyphenyl)propanoyl]hexahydro-2-pyridinecarboxylate;

4-(4-methoxyphenyl)butyl (2S)-1-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]hexahydro-2-pyridinecarboxylate;




3-cyclohexylpropyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)hexahydro-2-pyridinecarboxylate;

3-phenylpropyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)hexahydro-2-pyridinecarboxylate;

3-(3,4,5-trimethoxyphenyl)propyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)hexahydro-2-pyridinecarboxylate;

(1R)-2,2-dimethyl-1-phenethyl-3-butenyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)hexahydro-2-pyridinecarboxylate;

(1R)-1,3-diphenylpropyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)hexahydro-2-pyridinecarboxylate;

(1R)-1-cyclohexyl-3-phenylpropyl (2S)-1-(3,3-dimethyl-2-

oxopentanoyl)hexahydro-2-pyridinecarboxylate;

(1S)-1,3-diphenylpropyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)hexahydro-2-pyridinecarboxylate;

(1S)-1-cyclohexyl-3-phenylpropyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)hexahydro-2-pyridinecarboxylate;

(22aS)-15,15-dimethylperhydropyrido[2,1-c][1,9,4]dioxazacyclononadecine-1,12,16,17-tetraone;

(24aS)-17,17-dimethylperhydropyrido[2,1-c][1,9,4]dioxazacyclohenicosine-1,14,18,19-tetraone;

i



(3R,4R,23aS)-8-allyl-4,10-dimethyl-3-[2-(3-pyridyl)ethyl]-1,3,4,5,6,7,8,11,12,15,16,17,18,20,21,22,23,23a-octadecahydro-14H-pyrido[2,1-c][1,10,4]dioxazacycloicosine-1,7,14,17,18-pentaone;

(3R,4R,24aS)-8-allyl-4,10-dimethyl-3-[2-(3-pyridyl)ethyl]-1,3,4,5,6,7,8,11,12,14,15,16,17,18,19,21,22,23,24,24a-icosahydropyrido[2,1-c][1,11,4]dioxazacyclohenicosine-1,7,14,18,19-pentaone;

(3R,4R,25aS)-8-allyl-4,10-dimethyl-3-[2-(3-pyridyl)ethyl]-



T,1320 B' cont

132 B

1,3,4,5,6,7,8,11,12,15,16,17,18,19,20,22,23, 24,25,25a-icosahydro-14H-pyrido[2,1-c] [1,12,4]dioxazacyclodocosine-1,7,14,19,20-pentaone;



wherein n is 1; 2; or 3;



wherein n is 1; 2; or 3;

T,1340



B'cont

(1R)-1-(3-benzoylphenyl)-3-phenylpropyl (1R)-2-(3,3-dimethyl-2-oxopentanoyl)cyclohexane-1-carboxylate;

(1R)-1-[3-(diallylcarbamoyl)phenyl]-3-phenylpropyl; (1R)-2-(3,3-dimethyl-2-oxopentanoyl)cyclohexane-1-carboxylate;

T,1341



ethyl 1-(2-oxo-3-phenylpropanoyl)-2-piperidinecarboxylate;

ethyl 1-pyruvoyl-2-piperidinecarboxylate;



134 B

ethyl 1-(2-oxobutanoyl)-2-piperidinecarboxylate;

ethyl 1-(3-methyl-2-oxobutanoyl)-2-piperidinecarboxylate;

ethyl 1-(4-methyl-2-oxopentanoyl)-2-piperidinecarboxylate;

ethyl 1-(3,3-dimethyl-2-oxobutanoyl)-2-piperidinecarboxylate;

ethyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarboxylate;

4-[2-(ethyloxycarbonyl)piperidino]-2,2-dimethyl-3,4-dioxobutyl acetate;

ethyl 1-[2-(2-hydroxytetrahydro-2H-2-pyranyl)-2-oxoacetyl]-2-piperidinecarboxylate;

ethyl 1-[2-(2-methoxytetrahydro-2H-2-pyranyl)-2-oxoacetyl]-2-piperidinecarboxylate;

B' cont.

ethyl 1-[2-(1-hydroxycyclohexyl)-2-oxoacetyl]-2-piperidinecarboxylate;

ethyl 1-[2-(1-methoxycyclohexyl)-2-oxoacetyl]-2-piperidinecarboxylate;

ethyl 1-(2-cyclohexyl-2-oxoacetyl)-2-piperidinecarboxylate;

ethyl 1-(2-oxo-2-piperidinoacetyl)-2-piperidinecarboxylate;

ethyl 1-[2-(3,4-dihydro-2H-6-pyranyl)-2-oxoacetyl)-2-piperidinecarboxylate;

ethyl 1-(2-oxo-2-phenylacetyl)-2-piperidinecarboxylate;

ethyl 1-(4-methyl-2-oxo-1-thioxopentyl)-2-piperidinecarboxylate;

3-phenylpropyl 1-(2-hydroxy-3,3-dimethylpentanoyl)-2-piperidinecarboxylate;

(1R)-1-phenyl-3-(3,4,5-trimethoxyphenyl)propyl 1-(3,3-dimethylbutanoyl)-2-piperidinecarboxylate;



135 B

(1R)-1,3-diphenylpropyl 1-(benzylsulfonyl)-2-piperidinecarboxylate;

3-(3,4,5-trimethoxyphenyl)propyl 1-(benzylsulfonyl)-2-piperidinecarboxylate;

1-(2-[(2R,3R,6S)-6-[(2S,3E,5E,7E,9S,11R)-2,13-dimethoxy-3,9,11-trimethyl-12-oxo-3,5,7-tridecatrienyl]-2-hydroxy-3-methyltetrahydro-2H-2-pyranyl)-2-oxoacetyl)-2-piperidinecarboxylic acid;

methyl 1-(2-[(2R,3R,6S)-6-[(2S,3E,5E,7E,9S,11R)-2,13-dimethoxy-3,9,11-trimethyl-12-oxo-3,5,7-tridecatrienyl]-2-hydroxy-3-methyltetrahydro-2H-2-pyranyl)-2-oxoacetyl)-2-piperidinecarboxylate;

isopropyl 1-(2-[(2R,3R,6S)-6-[(2S,3E,5E,7E,9S,11R)-2,13-dimethoxy-3,9,11-trimethyl-12-oxo-3,5,7-tridecatrienyl]-2-hydroxy-3-methyltetrahydro-2H-2-pyranyl)-2-oxoacetyl)-2-piperidinecarboxylate;

benzyl 1-(2-[(2R,3R,6S)-6-[(2S,3E,5E,7E,9S,11R)-2,13-dimethoxy-3,9,11-trimethyl-12-oxo-3,5,7-tridecatrienyl]-2-hydroxy-3-methyltetrahydro-2H-2-pyranyl)-2-oxoacetyl)-2-piperidinecarboxylate;

1-phenylethyl 1-(2-[(2R,3R,6S)-6-[(2S,3E,5E,7E,9S,11R)-2,13-dimethoxy-3,9,11-trimethyl-12-oxo-3,5,7-tridecatrienyl]-2-hydroxy-3-methyltetrahydro-2H-2-pyranyl)-2-oxoacetyl)-2-piperidinecarboxylate;

(Z)-3-phenyl-2-propenyl 1-(2-[(2R,3R,6S)-6-[(2S,3E,5E,7E,9S,11R)-2,13-dimethoxy-3,9,11-trimethyl-12-oxo-3,5,7-tridecatrienyl]-2-

B' cont



136 B

hydroxy-3-methyltetrahydro-2H-2-pyranyl)-2-oxoacetyl)-2-piperidinecarboxylate;

3-(3,4-dimethoxyphenyl)propyl 1-(2-[(2R,3R,6S)-6-[(2S,3E,5E,7E,9S,11R)-2,13-dimethoxy-3,9,11-trimethyl-12-oxo-3,5,7-tridecatrienyl]-2-hydroxy-3-methyltetrahydro-2H-2-pyranyl)-2-oxoacetyl)-2-piperidinecarboxylate;

N2-benzyl-1-(2-[(2R,3R,6S)-6-[(2S,3E,5E,7E,9S,11R)-2,13-dimethoxy-3,9,11-trimethyl-12-oxo-3,5,7-tridecatrienyl]-2-hydroxy-3-methyltetrahydro-2H-2-pyranyl)-2-oxoacetyl)-2-piperidinecarboxylate;

N2-(3-phenylpropyl)-1-(2-[(2R,3R,6S)-6-[(2S,3E,5E,7E,9S,11R)-2,13-dimethoxy-3,9,11-trimethyl-12-oxo-3,5,7-tridecatrienyl]-2-hydroxy-3-methyltetrahydro-2H-2-pyranyl)-2-oxoacetyl)-2-piperidinecarboxylate;

B' cont.

T,370




wherein R is methyl (Me); or benzyl (Bn);



137 B




B' cont

wherein n = 2,



138

B

$R_1$ =



or



and

$R_2$ = Phe-o-tert-butyl;

B' cont.



wherein

| | |
|---|---|
| $R_1$ = m-$OCH_3$Ph, | $R_3$ = Val-o-tert-butyl; |
| $R_1$ = m-$OCH_3$Ph, | $R_3$ = Leu-o-tert-butyl; |
| $R_1$ = m-$OCH_3$Ph, | $R_3$ = Ileu-o-tert-butyl; |
| $R_1$ = m-$OCH_3$Ph, | $R_3$ = hexahydro-Phe-o-tert-butyl; |
| $R_1$ = m-$OCH_3$Ph, | $R_3$ = allylalanine-o-tert-butyl; |
| $R_1$ = B-naphthyl; | $R_3$ = Val-o-tert-butyl; |



139

B



wherein $R_1$ = $CH_2(CO)$-m-$OCH_3Ph$
$R_4$ = $CH_2Ph$
$R_5$ = $OCH_3$;

or

$R_1$ = $CH_2(CO)$-B-naphthyl
$R_4$ = $CH_2Ph$
$R_5$ = $OCH_3$;

B' cont



wherein

$R_1$ = m-$OCH_3Ph$
X = trans-CH=CH
$R_4$ = H
Y = OC(o)Ph;

$R_1$ = $OCH_3Ph$
X = trans-CH=CH
$R_4$ = H
Y = OC(o)$CF_3$;

$R_1$ = m-$OCH_3Ph$



140

B

X = trans-CH=CHI
$R_4$ = -
Y = -;

$R_1$ = m-$OCH_3$Ph
X = trans-CH=CH
$R_4$ = H
Y = $OCH_2CH=CH_2$;

$R_1$ = m-$OCH_3$Ph
X = C=O
$R_4$ = H
Y = Ph;




B' cont



141

B




B' cont

wherein

| | | |
|---|---|---|
| $R_1$ = H, | $R_2$ = OMe, and | $R_3$ = $CH_2OMe$; |
| $R_1$ = H, | $R_2$ = H, and | $R_3$ = H; |
| $R_1$ = Me, | $R_2$ = H, and | $R_3$ = H; |

(E)-3-(3,4-dichlorophenyl)-2-propenyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarboxylate;

(E)-3-(3,4,5-trimethoxyphenyl)-2-propenyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarboxylate;

(E)-3-phenyl-2-propenyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarboxylate;

(E)-3-((3-(2,5-dimethoxy)-phenylpropyl)phenyl)-2-propenyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarboxylate;

4-(4-methoxyphenyl)butyl 1-(2-oxo-2-phenylacetyl)-2-piperidinecarboxylate;

3-phenylpropyl 1-(2-oxo-2-phenylacetyl)-2-piperidinecarboxylate;

3-(3-pyridyl)propyl 1-(2-oxo-2-phenylacetyl)-2-piperidinecarboxylate;

3-(3-pyridyl)propyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarboxylate;



142

B

4-phenyl-1-(3-phenylpropyl)butyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarboxylate;
4-(4-methoxyphenyl)butyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarboxylate;
1-(4-methoxyphenethyl)-4-phenylbutyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarboxylate;
3-(2,5-dimethoxyphenyl)propyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarboxylate;
3-(1,3-benzodioxol-5-yl)propyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarboxylate;
1-phenethyl-3-phenylpropyl 1-(3,3-dimethyl-2-oxopentanoyl)-2-piperidinecarboxylate;
4-(4-methoxyphenyl)butyl 1-(2-cyclohexyl-2-oxoacetyl)- 2-piperidinecarboxylate;
3-cyclohexylpropyl 1-(2-cyclohexyl-2-oxoacetyl)-2-piperidinecarboxylate;
3-phenylpropyl 1-(2-cyclohexyl-2-oxoacetyl)-2-piperidinecarboxylate;
3-cyclohexylpropyl 1-(3,3-dimethyl-2-oxobutanoyl)-2-piperidinecarboxylate;
3-phenylpropyl 1-(3,3-dimethyl-2-oxobutanoyl)-2-piperidinecarboxylate;
4-(4-methoxyphenyl)butyl 1-(3,3-dimethyl-2-oxobutanoyl)-2-piperidinecarboxylate; and
4-phenyl-1-(3-phenylpropyl)butyl 1-(3,3-dimethyl-2-oxobutanoyl)-2-piperidinecarboxylate; and

pharmaceutically acceptable salts, esters, and solvates thereof.

26. (Twice Amended) [The method of claim 1, wherein the compound is] A method for treating a nerve-related vision disorder, improving vision, treating memory impairment, or enhancing memory performance in an animal, which comprises administering to said



143

animal an effective amount of Way-124,666, wherein the nerve-related vision disorder is selected from the group consisting of visual impairments; orbital disorders; disorders of the lacrimal apparatus; disorders of the eyelids; disorders of the conjunctiva; disorders of the cornea; cataract; disorders of the uveal tract; disorders of the retina; disorders of the optic nerve or visual pathways; free radical induced eye disorders and diseases; immunologically-mediated eye disorders and diseases; eye injuries; and symptoms and complications of eye disease, eye disorder, and eye injury.

3. (Twice Amended) [The method of claim 1, wherein the compound is] A method for treating a nerve-related vision disorder, improving vision, treating memory impairment, or enhancing memory performance in an animal, which comprises administering to said animal an effective amount of rapamycin, wherein the nerve-related vision disorder is selected from the group consisting of visual impairments; orbital disorders; disorders of the lacrimal apparatus; disorders of the eyelids; disorders of the conjunctiva; disorders of the cornea; cataract; disorders of the uveal tract; disorders of the retina; disorders of the optic nerve or visual pathways; free radical induced eye disorders and diseases; immunologically-mediated eye disorders and diseases; eye injuries; and symptoms and complications of eye disease, eye disorder, and eye injury.

B2 cont

4. (Twice Amended) [The method of claim 1, wherein the compound is] A method for treating a nerve-related vision disorder, improving vision, treating memory impairment, or enhancing memory performance in an animal, which comprises administering to said animal an effective amount of Rap-Pa, wherein the nerve-related vision disorder is selected from the group consisting of visual impairments; orbital disorders; disorders of the lacrimal



144

B

apparatus; disorders of the eyelids; disorders of the conjunctiva; disorders of the cornea; cataract; disorders of the uveal tract; disorders of the retina; disorders of the optic nerve or visual pathways; free radical induced eye disorders and diseases; immunologically-mediated eye disorders and diseases; eye injuries; and symptoms and complications of eye disease, eye disorder, and eye injury.

5, 8. (Twice Amended) [The method of claim 1, wherein the compound is] A method for treating a nerve-related vision disorder, improving vision, treating memory impairment, or enhancing memory performance in an animal, which comprises administering to said animal an effective amount of SLB-506, wherein the nerve-related vision disorder is selected from the group consisting of visual impairments; orbital disorders; disorders of the lacrimal apparatus; disorders of the eyelids; disorders of the conjunctiva; disorders of the cornea; cataract; disorders of the uveal tract; disorders of the retina; disorders of the optic nerve or visual pathways; free radical induced eye disorders and diseases; immunologically-mediated eye disorders and diseases; eye injuries; and symptoms and complications of eye disease, eye disorder, and eye injury.

Please add the following new claims:

9 27. The method of claim 1, wherein the nerve-related vision disorder is retinal ischemia.

10 28. The method of claim 27, wherein the retinal ischemia is selected from the group consisting of degeneration of retinal ganglion cells, degeneration of optic nerve axons, degeneration of myelin sheaths, ischemic optic neuropathy, and retinal vascular blockage.

11 29. The method of claim 1, wherein the nerve-related vision disorder is optic nerve transection.



128

B

30. The method of claim 29, wherein the optic nerve transection is selected from the group consisting of ganglion cell death after optic nerve transection and myelin degeneration after optic nerve transection.

31. The method of claim 1, wherein the nerve-related vision disorder is diabetes.

32. The method of claim 31, wherein the diabetes is selected from the group consisting of diabetes from degeneration and diabetic retinopathy.

33. The method of claim 1, wherein the nerve-related vision disorder is macular degeneration.

34. The method of claim 1, wherein the nerve-related vision disorder is glaucoma related degeneration.

35. The method of claim 1, wherein the nerve-related vision disorder is cataract related degeneration.

36. The method of claim 1, wherein the nerve-related vision disorder is a detached retina.

37. The method of claim 1, wherein the nerve-related vision disorder is inflammation related degeneration.

38. The method of claim 1, wherein the nerve-related vision disorder is photoreceptor degeneration.

39. The method of claim 1, wherein the nerve-related vision disorder is optic neuritis.

40. The method of claim 1, wherein the nerve-related vision disorder is dry eye degeneration.

41. The method of claim 6, wherein the nerve-related vision disorder is retinal ischemia.

42. The method of claim 41, wherein the retinal ischemia is selected from the group consisting of degeneration of retinal ganglion cells, degeneration of optic nerve axons, degeneration of myelin sheaths, ischemic optic neuropathy, and retinal vascular blockage.



129

43. The method of claim 6, wherein the nerve-related vision disorder is optic nerve transection.

44. The method of claim 43, wherein the optic nerve transection is selected from the group consisting of ganglion cell death after optic nerve transection and myelin degeneration after optic nerve transection.

45. The method of claim 6, wherein the nerve-related vision disorder is diabetes.

46. The method of claim 45, wherein the diabetes is selected from the group consisting of diabetes from degeneration and diabetic retinopathy.

47. The method of claim 6, wherein the nerve-related vision disorder is macular degeneration.

48. The method of claim 6, wherein the nerve-related vision disorder is glaucoma related degeneration.

49. The method of claim 6, wherein the nerve-related vision disorder is cataract related degeneration.

50. The method of claim 6, wherein the nerve-related vision disorder is a detached retina.

51. The method of claim 6, wherein the nerve-related vision disorder is inflammation related degeneration.

52. The method of claim 6, wherein the nerve-related vision disorder is photoreceptor degeneration.

53. The method of claim 6, wherein the nerve-related vision disorder is optic neuritis.

54. The method of claim 6, wherein the nerve-related vision disorder is dry eye degeneration.

55. The method of claim 1, wherein the nerve-related vision disorder is retinal ischemia.

56. The method of claim 55, wherein the retinal ischemia is selected from the group consisting of degeneration of retinal ganglion cells, degeneration of optic nerve axons, degeneration of myelin sheaths, ischemic optic neuropathy, and retinal vascular blockage.



B3 cont

147

B

57. The method of claim 31, wherein the nerve-related vision disorder is optic nerve transection.

58. The method of claim 57, wherein the optic nerve transection is selected from the group consisting of ganglion cell death after optic nerve transection and myelin degeneration after optic nerve transection.

59. The method of claim 31, wherein the nerve-related vision disorder is diabetes.

60. The method of claim 59, wherein the diabetes is selected from the group consisting of diabetes from degeneration and diabetic retinopathy.

61. The method of claim 31, wherein the nerve-related vision disorder is macular degeneration.

62. The method of claim 31, wherein the nerve-related vision disorder is glaucoma related degeneration.

63. The method of claim 31, wherein the nerve-related vision disorder is cataract related degeneration.

64. The method of claim 31, wherein the nerve-related vision disorder is a detached retina.

65. The method of claim 31, wherein the nerve-related vision disorder is inflammation related degeneration.

66. The method of claim 31, wherein the nerve-related vision disorder is photoreceptor degeneration.

67. The method of claim 31, wherein the nerve-related vision disorder is optic neuritis.

68. The method of claim 31, wherein the nerve-related vision disorder is dry eye degeneration.

69. The method of claim 8, wherein the nerve-related vision disorder is retinal ischemia.

70. The method of claim 69, wherein the retinal ischemia is selected from the group consisting of degeneration of retinal ganglion cells, degeneration of optic nerve axons, degeneration of myelin sheaths, ischemic optic neuropathy, and retinal vascular blockage.



148

71. The method of claim 8, wherein the nerve-related vision disorder is optic nerve transection.

72. The method of claim 71, wherein the optic nerve transection is selected from the group consisting of ganglion cell death after optic nerve transection and myelin degeneration after optic nerve transection.

73. The method of claim 8, wherein the nerve-related vision disorder is diabetes.

74. The method of claim 73, wherein the diabetes is selected from the group consisting of diabetes from degeneration and diabetic retinopathy.

75. The method of claim 8, wherein the nerve-related vision disorder is macular degeneration.

76. The method of claim 8, wherein the nerve-related vision disorder is glaucoma related degeneration.

77. The method of claim 8, wherein the nerve-related vision disorder is cataract related degeneration.

78. The method of claim 8, wherein the nerve-related vision disorder is a detached retina.

79. The method of claim 8, wherein the nerve-related vision disorder is inflammation related degeneration.

80. The method of claim 8, wherein the nerve-related vision disorder is photoreceptor degeneration.

81. The method of claim 8, wherein the nerve-related vision disorder is optic neuritis.

82. The method of claim 8, wherein the nerve-related vision disorder is dry eye degeneration.

83. The method of claim 8, wherein the nerve-related vision disorder is retinal ischemia.

84. The method of claim 83, wherein the retinal ischemia is selected from the group consisting of degeneration of retinal ganglion cells, degeneration of optic nerve axons, degeneration of myelin sheaths, ischemic optic neuropathy, and retinal vascular blockage.



149

B

85. The method of claim 9, wherein the nerve-related vision disorder is optic nerve transection.

86. The method of claim 85, wherein the optic nerve transection is selected from the group consisting of ganglion cell death after optic nerve transection and myelin degeneration after optic nerve transection.

87. The method of claim 9, wherein the nerve-related vision disorder is diabetes.

88. The method of claim 87, wherein the diabetes is selected from the group consisting of diabetes from degeneration and diabetic retinopathy.

89. The method of claim 9, wherein the nerve-related vision disorder is macular degeneration.

90. The method of claim 9, wherein the nerve-related vision disorder is glaucoma related degeneration.

91. The method of claim 9, wherein the nerve-related vision disorder is cataract related degeneration.

92. The method of claim 9, wherein the nerve-related vision disorder is a detached retina.

93. The method of claim 9, wherein the nerve-related vision disorder is inflammation related degeneration.

94. The method of claim 9, wherein the nerve-related vision disorder is photoreceptor degeneration.

95. The method of claim 9, wherein the nerve-related vision disorder is optic neuritis.

96. The method of claim 9, wherein the nerve-related vision disorder is dry eye degeneration.

---

**REMARKS**

Upon entry of the above amendments, claims 1, 6-9, 21, 23-24, and 27-96 are pending in the application. The amendments do not add any new matter under 35 U.S.C. §132. Basis for the term